PMID

Data

Article Title

Organization

Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

Pfizer Inc

Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.

Takeda Pharmaceutical Co., Ltd

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

Pfizer Inc

Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.

Hoffmann-La Roche Inc

Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.

F. Hoffmann-La Roche Inc

Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2.

China Pharmaceutical University

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.

Bristol-Myers Squibb Research & Development

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.

Pfizer Inc.

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.

Japan Tobacco Inc.

Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.

University of Strathclyde

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.

TBA

Identification of

TBA

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

Pfizer Inc.

Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.

Janssen Research and Development

Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.

China Pharmaceutical University

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

TBA

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.

West China Hospital of Sichuan University

Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.

Astellas Pharma Inc.

Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.

Eberhard-Karls-University Tuebingen

Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.

Bristol-Myers Squibb Research and Development

Discovery of highly potent, selective, covalent inhibitors of JAK3.

Bristol-Myers Squibb Research and Development

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Pfizer Inc